Washington Capital Management Inc. Takes Position in Becton, Dickinson and Company $BDX

Washington Capital Management Inc. acquired a new position in Becton, Dickinson and Company (NYSE:BDX) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 5,245 shares of the medical instruments supplier’s stock, valued at approximately $982,000.

Several other hedge funds also recently modified their holdings of the business. SOA Wealth Advisors LLC. lifted its stake in Becton, Dickinson and Company by 256.8% in the third quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 95 shares during the period. Bell Investment Advisors Inc increased its stake in Becton, Dickinson and Company by 474.1% in the second quarter. Bell Investment Advisors Inc now owns 155 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 128 shares in the last quarter. Bank of Jackson Hole Trust boosted its position in shares of Becton, Dickinson and Company by 85.6% during the second quarter. Bank of Jackson Hole Trust now owns 206 shares of the medical instruments supplier’s stock worth $35,000 after purchasing an additional 95 shares in the last quarter. CVA Family Office LLC raised its stake in Becton, Dickinson and Company by 79.5% during the 2nd quarter. CVA Family Office LLC now owns 219 shares of the medical instruments supplier’s stock worth $38,000 after buying an additional 97 shares during the period. Finally, CoreFirst Bank & Trust bought a new stake in shares of Becton, Dickinson and Company in the second quarter worth about $38,000. Institutional investors own 86.97% of the company’s stock.

Insider Activity

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 217 shares of the firm’s stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $176.58, for a total transaction of $38,317.86. Following the completion of the sale, the director directly owned 35,816 shares in the company, valued at $6,324,389.28. This trade represents a 0.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Michael David Garrison sold 629 shares of the company’s stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $196.03, for a total value of $123,302.87. Following the completion of the transaction, the executive vice president directly owned 13,105 shares in the company, valued at $2,568,973.15. The trade was a 4.58% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 1,052 shares of company stock worth $201,235 over the last three months. Insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Stock Performance

NYSE BDX opened at $208.23 on Friday. The firm has a market capitalization of $59.33 billion, a P/E ratio of 35.72, a price-to-earnings-growth ratio of 2.29 and a beta of 0.23. The company has a current ratio of 1.11, a quick ratio of 0.64 and a debt-to-equity ratio of 0.69. The firm’s fifty day moving average price is $195.30 and its two-hundred day moving average price is $189.07. Becton, Dickinson and Company has a 1 year low of $162.29 and a 1 year high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, November 6th. The medical instruments supplier reported $3.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.92 by $0.04. The business had revenue of $5.89 billion during the quarter, compared to the consensus estimate of $5.91 billion. Becton, Dickinson and Company had a net margin of 7.68% and a return on equity of 16.42%. Becton, Dickinson and Company’s revenue was up 8.3% on a year-over-year basis. During the same period last year, the business posted $3.81 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. As a group, research analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, December 31st. Shareholders of record on Monday, December 8th were given a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a yield of 2.0%. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. The ex-dividend date of this dividend was Monday, December 8th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 72.04%.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on BDX shares. Stifel Nicolaus boosted their price objective on Becton, Dickinson and Company from $210.00 to $215.00 and gave the company a “buy” rating in a research report on Wednesday, January 7th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Wednesday, October 8th. Jefferies Financial Group boosted their price objective on shares of Becton, Dickinson and Company from $215.00 to $220.00 and gave the company a “buy” rating in a research report on Wednesday, December 10th. Piper Sandler lowered their target price on Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating for the company in a report on Friday, November 7th. Finally, Bank of America boosted their price target on Becton, Dickinson and Company from $190.00 to $207.00 and gave the company a “neutral” rating in a report on Monday, January 5th. Four equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $207.64.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.